Skip to main content
Erschienen in: Rheumatology International 12/2020

18.09.2020 | COVID-19 | Observational Research Zur Zeit gratis

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

verfasst von: Jesús Loarce-Martos, Antía García-Fernández, Fernando López-Gutiérrez, Verónica García-García, Laura Calvo-Sanz, Iván del Bosque-Granero, M. Andreína Terán-Tinedo, Alina Boteanu, Javier Bachiller-Corral, Mónica Vázquez-Díaz

Erschienen in: Rheumatology International | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study is to describe the characteristics and outcomes of rheumatic and musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this descriptive study, RMD patients who were treated with rituximab in the last 12 months at the Rheumatology Department of our hospital were screened for SARS-CoV-2 infection via telephone interview and a comprehensive review of clinical health records (01/02/2020–26/05/2020). Those with probable or confirmed SARS-CoV-2 infection were included. In total, 76 patients were screened. Of these, 13 (17.1%) had suspected or confirmed SARS-CoV-2 infection. With regard to these 13 patients, the median age at coronavirus disease (COVID-19) diagnosis was 68 years (range 28–76 years) and 8 (61.5%) were female. Five patients had rheumatoid arthritis, three had systemic vasculitis, two had Sjögren syndrome, and two had systemic lupus erythematosus. Additionally, seven patients (53.8%) had pulmonary involvement secondary to RMD. Eight patients (61.5%) developed severe disease leading to hospitalization, and seven developed bilateral pneumonia and respiratory insufficiency. Of the eight hospitalized patients, five (62.5%) fulfilled the acute respiratory distress syndrome criteria and three developed a critical disease and died. Our cohort had a high rate of severe disease requiring hospitalization (61.5%), with bilateral pneumonia and hyperinflammation leading to a high mortality rate (23.1%). Treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD. However, further study is required to confirm this association.
Literatur
13.
Zurück zum Zitat Monti S, Balduzzi S, Delvino P et al (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79:667–668CrossRefPubMed Monti S, Balduzzi S, Delvino P et al (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79:667–668CrossRefPubMed
21.
Zurück zum Zitat Luu VP, Vazquez MI, Zlotnik A (2014) B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity 47:1–12CrossRefPubMed Luu VP, Vazquez MI, Zlotnik A (2014) B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity 47:1–12CrossRefPubMed
Metadaten
Titel
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
verfasst von
Jesús Loarce-Martos
Antía García-Fernández
Fernando López-Gutiérrez
Verónica García-García
Laura Calvo-Sanz
Iván del Bosque-Granero
M. Andreína Terán-Tinedo
Alina Boteanu
Javier Bachiller-Corral
Mónica Vázquez-Díaz
Publikationsdatum
18.09.2020
Verlag
Springer Berlin Heidelberg
Schlagwort
COVID-19
Erschienen in
Rheumatology International / Ausgabe 12/2020
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04699-x

Weitere Artikel der Ausgabe 12/2020

Rheumatology International 12/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.